Clinical Scorecard: Development of a Cynomolgus Macaque Model for Investigating Respiratory Illness Induced by Human Adenovirus Type 55
At a Glance
Category
Detail
Condition
Respiratory illness and severe pneumonia caused by Human Adenovirus type 55 (HAdV-55)
Key Mechanisms
HAdV-55 infection induces respiratory symptoms, peri-bronchial lung consolidation, granulomatous inflammation, macrophage infiltration, and cytokine responses including early IFN-γ, IFN-β, IL-6 induction with delayed IL-8 elevation and IL-4 suppression
Target Population
Individuals susceptible to HAdV-55 including military recruits, young children, immunocompromised patients, elderly in long-term care, and community populations
Care Setting
Hospital and clinical settings managing acute respiratory infections and pneumonia
Key Highlights
HAdV-55 is an emerging respiratory pathogen causing outbreaks with high morbidity and mortality, especially in crowded environments.
Cynomolgus macaques infected intranasally and intratracheally with HAdV-55 develop clinical, radiological, hematological, and immunological features closely resembling human disease.
The macaque model enables preclinical evaluation of vaccines and therapeutics targeting HAdV-55 respiratory infection.
Guideline-Based Recommendations
Diagnosis
Identify HAdV-55 infection by clinical signs including high fever, cough, dyspnea, and radiological findings such as peri-bronchial consolidation and ground-glass opacities.
Laboratory testing should include hematologic analysis showing neutrophilia and cytokine profiling for IFN-γ, IL-4, and IL-10 elevations.
Management
Supportive care for respiratory symptoms and monitoring for progression to hypoxemia and respiratory failure.
Consider mechanical ventilation in severe cases with acute respiratory distress syndrome.
Monitoring & Follow-up
Regular clinical assessment of respiratory rate, heart rate, and weight loss.
Imaging studies to monitor lung involvement and progression.
Hematologic and cytokine profiling to assess immune response dynamics.
Risks
High hospitalization rates up to 40% during outbreaks.
Case fatality rates ranging from approximately 5% to 16% in severe or outbreak settings.
Risk of respiratory failure requiring intensive care.
Patient & Prescribing Data
Patients with confirmed or suspected HAdV-55 respiratory infection, including high-risk groups such as military recruits and immunocompromised individuals.
No specific antiviral treatment detailed; management focuses on supportive care and monitoring. The macaque model supports development and preclinical testing of vaccines and therapeutics.
Clinical Best Practices
Use of nonhuman primate models like cynomolgus macaques to study HAdV-55 pathogenesis and immune responses.
Employ intranasal and intratracheal routes for infection to mimic natural respiratory exposure.
Monitor comprehensive clinical, hematologic, cytokine, imaging, and histopathological parameters to evaluate disease progression and therapeutic efficacy.
by Sang Hwan Seo, Jung-ah Choi, Dae-Im Jung, Yunjeong Park, Eunji Yang, Chanmi Kim, Minkyung Ko, Seung Ho Baek, Jung Joo Hong, Soon-Hwan Kwon, Won-Tae Kim, Jun Young Lee, Manki Song
